Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential

International Journal of Nanomedicine

Volumn 1, Issue 3, 2006, Pages 297-315

  Immordino, Maria Laura ^a   Dosio, Franco ^a   Cattel, Luigi ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Immunoliposomes; Liposomes; Stealth liposomes; Targeted liposomes

Indexed keywords

DRUG; DRUG CARRIER; LIPOSOME;

CHEMICAL MODEL; CHEMISTRY; DRUG FORMULATION; FORECASTING; METHODOLOGY; REVIEW;

DRUG CARRIERS; DRUG COMPOUNDING; FORECASTING; LIPOSOMES; MODELS, CHEMICAL; PHARMACEUTICAL PREPARATIONS;

EID: 34548482374     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: None     Document Type: Review

References (158)

1. Adams GP, Weiner LM. 2005. Monoclonal antibody therapy of cancer. Nat Biotechnol, 23:1147-57.
2. Adlakha-Hutcheon G, Bally MB, Shew CR, et al. 1999. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity. Nat Biotechnol, 17:775-9.
3. Agrawal AK, Gupta CM. 2000. Tuftsin-bearing liposomes in treatment of macrophage-based infections. Adv Drug Deliv Rev, 41:135-46.
4. Alberts DS, Muggia FM, Carmichael J, et al. 2004. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol, 31(Suppl 13):53-90.
5. Allen C, Dos SN, Gallagher R, et al. 2002 Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Biosc Rep, 22:225-50.
6. Allen TM, Hansen C, Martin F, et al. 1991. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim Biophys Acta, 1066:29-36.
7. Allen TM, Hansen C, Rutledge J. 1989. Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim Biophys Acta, 981:27-35.
8. Allen TM, Hansen CB, Guo LSS. 1993. Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection. Biochim Biophys Acta, 1150:9-16.
9. Allen TM, Martin FJ. 2004, Advantages of liposomal delivery systems for anthracyclines. Semin Oncol, 31(Suppl 13):5-15.
10. Alving CR. 1978. Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. Proc Natl Acad Sci U S A, 75:2959-63.
11. Andreff M, Estey EH. 2004. Method of cancer treatment [patent]. US2004057989.
12. Anonymous. 1999. Nystatin-liposomal. AR 121, Nyotran. Drugs R D, 1:181-3.
13. Anonymous. 2004. Vincristine liposomal--INEX: lipid-encapsulated vincristine, onco TCS, transmembrane carrier system--vincristine, vincacine, vincristine sulfate liposomes for injection, VSLI. Drugs R D, 5:119-23.
14. Arifin DR, Palmer AF. 2005. Physical properties and stability mechanisms of poly(ethylene glycol) conjugated liposome encapsulated hemoglobin dispersions. Artif Cells Blood Substit Immobil Biotechnol, 33:137-62.
15. Arikan S, Rex JH. 2001. Nystatin LF (Aronex/Abbott). Curr Opin Investig Drugs, 2:488-495.
16. Asahi M, Rammohan R, Sumii T, et al. 2003. Antiactin-targeted immunoliposomes ameliorate tissue plasminogen activator-induced hemorrhage after focal embolic stroke. J Cereb Blood Flow Met, 23:895-9.
17. Asai T, Oku N. 2005, Liposomalized oligopeptides in cancer therapy. Methods Enzymol, 391:163-76.
18. Awada A, Gil T, Sales F, et al. 2004. Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers. Anticancer Drugs, 15:499-502.
19. Babai I, Samira S, Barenholz Y, et al. 1999. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. I. Vaccine characterization and efficacy studies in mice. Vaccine, 17:1223-38.
20. Banerjee R, Tyagi P, Li S, et al. 2004. Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer, 112:693-700.
21. Baselga J, Metselaar JM. 2000. Monoclonal antibodies: Clinical applications: Monoclonal antibodies directed against growth factor receptors. In Rosenburg SA (ed). Principles and practice of biological therapy of cancer. Philadelphia: Lippincott Williams, Wilkins: p 475-89.
22. Basu MK, Lala S. 2004. Macrophage specific drug delivery in experimental leishmaniasis. Curr Mol Med, 4:681-9.
23. Blume GaCG. 1993. Molecular mechanism of the lipid vesicle longevity in vivo. Biochim Biophys Acta, 1146:157-68.
24. Bomgaars L, Geyer JR, Franklin J, et al. 2004 Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol, 22:3916-21.
25. Boulikas T, Stathopoulos GP, Volakakis N, et al. 2005. Systemic Lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res, 25:3031-9.
26. Bradley AJ, Devine DV, Ansell SM, et al. 1998. Inhibition of liposome-induced complement activation by incorporated poly(ethylene glycol)-lipids. Arch Biochem Biophys, 357:185-94.
27. Bramwell VW, Eyles JE, Oya, AH. 2005. Particulate delivery systems for biodefense subunit vaccines. Adv Drug Del Rev, 57:1247-65.
28. Briasoulis E, Karavasilis V, Tzamakou E, et al. 2004. Interaction pharmacokinetics of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel. Cancer Chemother Pharmacol, 53:452-7.
29. Caliceti P, Veronese FM. 2003. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Del Rev, 55:1261-77.
30. Chen T, Palmer LR, Fenske DB, et al. 2004. Distal cationic poly(ethylene glycol) lipid conjugates in large unilamellar vesicles prepared by extrusion enhance liposomal cellular uptake. J Liposome Res, 14:155-73.
31. Chen WC, Huang L. 2005. Non-viral vector as vaccine carrier. Adv Genet, 54:315-37.
32. Chonn A, Cullis PR, Devine DV. 1991. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J Immunol, 146:4234-41.
33. Chonn A, Semple SC, Cullis PR. 1992 Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J Biol Chem, 267:18759-765.
34. Chonn A, Semple SC, Cullis PR. 1995. Beta 2-glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of "non-self" particles. J Biol Chem, 270:25845-9.
35. Copland MJ, Rades T, Davies NM, et al. 2005. Lipid based particulate formulations for the delivery of antigen. Immunol Cell Biol, 83:97-105.
36. Corvo ML, Boerman OC, Oyen WJ, et al. 1999. Intravenous administration of superoxide dismutase entrapped in long circulating liposomes. II. In vivo fate in a rat model of adjuvant arthritis. Biochim Biophys Acta, 1419:325-34.
37. Crosasso P, Ceruti M, Brusa P, et al. 2000. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J Control Release, 63:19-30.
38. Dagar S, Krishnadas A, Rubinstein I, et al. 2003. VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies. J Control Release, 91:123-33.
39. Damen J. 2005. Transfer and exchange of phospholipid between small unilamellar liposomes and rat plasma high-density lipoproteins: dependence on cholesterol and phospholipid composition. Biochim Biophys Acta, 665:538-45.
40. Dark GG, Calvert AH, Grimshaw R, et al. 2005. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.[see comment]. J Clin Oncol, 23:1859-66.
41. Dayton PA, Ferrara KW. 2002. Targeted imaging using ultrasound. J Magn Reson Imaging, 16:362-77.
42. de Gennes PG. 1980. Conformations of polymers attached to an interface, Macromolecules, 13:1069-75.
43. Devine DV, Wong K, Serrano K, et al. 1994. Liposome-complement interactions in rat serum: Implications for liposome survival studies. Biochim Biophys Acta, 1191:43-51.
44. Dreborg S, Akerblom EB. 1990. Immunotherapy with monomethoxy-polyethylene glycol modified allergenes. Crit Rev Ther Drug Carrier Syst:315-65.
45. Drummond DC, Meyer O, Hong K, et al. 1999. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev, 51:691-743.
46. Eichhorn ME, Becker S, Strieth S. et al 2006. Paclitaxel encapsulated in cationic lipid complexes (MBT-0206) impairs functional tumor vascular properties as detected by dynamic contrast enhanced magnetic resonance imaging. Cancer Biol Ther, 5. In press.
47. Falcone DJ. 1986. Fluorescent opsonization assay: binding of plasma fibronectin to fibrinderivatized fluorescent particles does not change their uptake by macrophages. J Leukoc Biol, 39:1-12.
48. Felnerova D, Viret JF, Gluck R, et al. 2004, Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol, 15:518-29.
49. Funato KYRKH. 1992. Contribution of complement system on destabiliza-tion of liposomes composed of hydrogenated egg phosphatidylcholine in rat fresh plasma. Biochim Biophys Acta, 1103:204.
50. Gabizon A, Papahadjopoulos D. 1988. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A, 85:6949-53.
51. Gabizon AA, Muggia FM. 1998. Long circulating liposomes: old drugs, new therapeutics. Springer-Verlag and Landes Bioscience.
52. Gulati M, Grover M, Singh S, et al. 1998. Lipophilic drug derivatives in liposomes. Int J Pharm, 165:129-68.
53. Gupta B, Levchenko TS, Torchilin VP. 2005. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev, 57:637-51.
54. Hamaguchi T, Matsumura Y, Nakanishi Y, et al. 2004. Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. Cancer Sci, 95:608-13.
55. Han I Ling YH, al-Baker S, et al. 1993. Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells. Cancer Res, 53:4913-19.
56. Harashima H, Sakata K, Funato K, et al. 1994. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm Res, 11:402-6.
57. Harata M, Soda Y, Tani K, et al. 2004. CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells. Blood, 104:1442-9.
58. Harrington KJ, Lewanski CR, Northcote AD, et al. 2001. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol, 12:493-6.
59. Harrington KJ, Rowlinson-Busza G, Syrigos KN, et al. 2000a. Influence of tumour size on uptake of(111)ln-DTPA-labelled pegylated liposomes in a human tumour xenograft model. Br J Cancer, 83:684-8.
60. Harrington KJ, Rowlinson-Busza G, Syrigos KN, et al. 2000b. Biodistribu-tion and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies. Br J Cancer, 83:232-8.
61. Harris JM. 1992. Poly(ethylene glycol) chemistry: biotechnical and biomedical applications. Plenum Press.
62. Hau P, Fabel K, Baumgart U, et al. 2004. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer, 100:1199-207.
63. Hussein MA, Anderson KC. 2004. Role of liposomal anthracyclines in the treatment of multiple myeloma. Semin Oncol, 31(Suppl 13):147-60.
64. Immordino ML, Brusa P, Arpicco S, et al. 2003. Preparation, characteriza-tion, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J Control Release, 91:417-29.
65. Ishida, O. Maruyama, K. Tanahashi, H, et al. 2001, Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm Res, 18:1042-8.
66. Ishida T, Harada M, Wang XY, et al. 2005. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J Control Release, 105:305-17.
67. Ishida T, Harashima H, Kiwada H. 2002. Liposome clearance. Biosci Rep, 22:197-224.
68. Jaeckle KA, Phuphanich S, Bent MJ, et al. 2001. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer, 84:157-63.
69. Johnstone SA, Masin D, Mayer L, et al. 2001. Surface associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages. Biochim Biophys Acta, 1513:25-37.
70. Katsaros D, Oletti MV, Rigault de la Longrais A, et al. 2005. Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma. Ann Oncol, 16:300-6.
71. Kim ES, Lu C, Khuri FR, et al. 2001. A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. Lung Cancer, 34:427-32.
72. Kondo M, Asai T, Katanasaka Y, et al. 2004. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int J Cancer, 108:301-6.
73. Kraut EH, Fishman MN, Lorusso PM, et al. 2004. Pharmacogenomic and pharmacokinetic assessment of liposome encapsulated SN-38 (LE-SN38) in advanced cancer patients, J Clin Oncol (Meeting Abstracts), 22:2501.
74. Krown SE, Northfelt DW, Osoba D, et al. 2004. Use of liposomal anthracyclines in Kaposi's sarcoma. Semin Oncol, 31(Suppl 13):36-52.
75. Laverman P, Carstens MG, Boerman OC, et al. 2001. Factors affecting the accelerated blood clearance of polyethylene glycol liposomes upon repeated injection. J Pharmacol Exp Ther, 298:607-12.
76. Lee TY, Wu HC, Tseng YL, et al. 2004. A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery. Cancer Res, 64:8002-8.
77. Liu D, Mori A, Huang L. 1992. Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. Biochim Biophys Acta, 1104:95-101.
78. Lokling KE, Fossheim SL, Klaveness J, et al. 2004. Biodistribution of pH-responsive liposomes for MRI and a novel approach to improve the pH-responsiveness. J Control Release, 98:87-95.
79. Lopes De Menezes DE, Kirchmeier MJ, Gagne J-F, et al. 1999. Cellular trafficking and cytotoxicity of anti-CD19-targeted liposomal doxorubicin in B lymphoma cells. J Liposome Res, 9:199-228.
80. Lu C, Perez-Soler R, Piperdi B, et al. 2005. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J Clin Oncol, 23:3495-501.
81. Lukyanov AN, Elbayoumi TA, Chakilam AR, et al. 2004. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Release, 100:135-44.
82. Lundberg BB, Griffiths G, Hansen HJ. 2000 Specific binding of sterically stabilized anti-B-cell immunoliposomes and cytotoxicity of entrapped doxorubicin. Int J Pharm, 205:101-8.
83. Lyass O, Uziely B, Ben-Yosef R, et al. 2000. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (DOXIL) in metastatic breast carcinoma. Cancer, 89:1037-47.
84. Maeda H, Sawa T, Konno T. 2001. Mechanism of tumor targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release, 74:47-61.
85. Mahato RI. 2005. Water insoluble and soluble lipids for gene delivery. Adv Drug Deliv Rev, 57:699-712.
86. Mahmood I, Green MD. 2005. Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin Pharmacokinet, 44:331-47.
87. Mamot C, Drummond DC, Greiser U, et al. 2003. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR-and EGFRvIII-overexpressing tumor cells. Cancer Res, 63:3154-61.
88. Mantripragada S. 2002. A lipid based depot (DepoFoam technology) for sustained release drug delivery. Prog Lipid Res, 41:392-406.
89. Marjan J, Xie Z, Devine D. 1994. Liposome-induced activation of the classical complement pathway does not require immunoglobulin. Biochim Biophys Acta, 1192:35-44.
90. Maruyama K, Ishida O, Kasaoka S, et al. 2004. Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT). J Control Release, 98:195-207.
91. Maruyama K, Okuizumi S, Ishida O, et al. 1994. Phosphatidyl polyglycerols prolong liposome circulation in vivo. Int J Pharm, 111:103-7.
92. Matsumura Y, Gotoh M, Muro K, et al. 2004. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol, 15:517-25.
93. Medina OP, Zhu Y, Kairemo K. 2004. Targeted liposomal drug delivery in cancer. Curr Pharm Des, 10:2981-9.
94. Metselaar JM, Bruin P, de Boer LW, et al. 2003. A novel family of L-amino acid-based biodegradable polymer-lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity. Bioconjug Chem, 14:1156-64.
95. Meyer O, Kirpotin D, Hong K, et al. 1998. Cationic liposomes coated with polyethylene glycol as carriers for oligonucleotides. J Biol Chem, 273:15621-7.
96. Moghimi SM, Muir IS, Illum L, et al. 1993. Coating particles with a block copolymer (Poloxamine 908) suppresses opsonization but permits the activity of dysopsonins in the serum. Biochim Biophys Acta, 1179:157-65.
97. Moghimi SM, Szebeni J. 2003. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res, 42:463-78.
98. Monfardini C, Veronese FM. 1998. Stabilization of substances in circulation. Bioconj Chem, 9:418-50.
99. Mora M, Sagrista ML, Trombetta D, et al. 2002. Design and characterization of liposomes containing long-chain N-acylPEs for brain delivery: penetration of liposomes incorporating GM1 into the rat brain. Pharm Res, 19:1430-8.
100. Morawski AM, Lanza GA, Wickline SA. 2005. Targeted contrast agents for magnetic resonance imaging and ultrasound. Curr Opin Biotechnol, 16:89-92.
101. Mukherjee A, Prasad TK, Rao NM, et al. 2005. Haloperidol-associated stealth liposomes: a potent carrier for delivering genes to human breast cancer cells. J Biol Chem, 280:15619-27.
102. Murai M, Aramki Y, Tsuchiya S. 1995. Identification of the serum factor required for liposome primed activation of mouse peritoneal macrophages: modified 2-macroglobulin enhances Fc gamma receptor mediated phagocytosis of opsonized sheep red blood cells. Immunology, 86:64-70.
103. Needham D, McIntosh TJ, Lasic DD. 1992. Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. Biochim Biophys Acta, 1108:40-8.
104. Nellis DF, Ekstrom DL, Kirpotin DB, et al. 2005a. Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol Prog, 21:205-20.
105. Nellis DF, Giardina SL, Janini GM, et al. 2005b. Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol Prog, 21:221-32.
106. Nishikawa KAHIK. 1990. Scavanger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophages. J Biol Chem, 265:5226-31.
107. Oja CDM, Semple SC, Chonn A, et al. 1996. Influence of dose on liposome clearance: critical role of blood proteins. Biochim Biophys Acta, 1281:31-7.
108. Oku N, Namba Y. 2005. Glucuronate-modified, long-circulating liposomes for the delivery of anticancer agents. Methods Enzymol, 391:145-62.
109. Oussoren C, Storm G. 1997. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: III. Influence of surface modification with poly(ethyleneglycol). Pharm Res, 14:1479-84.
110. Ozpolat B, Lopez-Berestein G, Adamson P, et al. 2003. Pharmacokinetics of intravenously administered liposomal all-trans-retinoic acid (ATRA) and orally administered ATRA in healthy volunteers. J Pharm Pharm Sc, 6:292-301.
111. Palmer LR, Chen T, Lam AM, et al. 2003. Transfection properties of stabilized plasmid-lipid particles containing cationic PEG lipids. Biochim Biophys Acta, 1611:204-16.
112. Park JW, Hong K, Kirpotin DB, et al. 2002. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res, 8:1172-81.
113. Park YS, Maruyama K, Huang L. 1992. Some negatively charged phospholipid derivatives prolong the liposome circulation in vivo. Biochim Biophys Acta, 1108:257-60.
114. Pastorino F, Brignole C, Marimpietri D, et al. 2003. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res, 63:86-92.
115. Patel HM. 1992. Serum opsonins and liposomes: their interaction and opsonophagocytosis. Crit Rev Ther Drug Carrier Syst, 9:39-90.
116. Phillips WT, Klipper RW, Awasthi VD, et al. 1999. Polyethylene glycol-modified liposome-encapsulated hemoglobin: a long circulating red cell substitute. J Pharmacol Exp Ther, 288:665-70.
117. Powell GM. 1980. Polyethylene glycol. In Davidson RL (ed). Handbook of water soluble gums and resins. McGraw-Hill. p 18-31.
118. Price ME, Cornelius RM, Brash JL. 2001. Protein adsorption to polyethylene glycol modified liposomes from fibrinogen solution and from plasma. Biochim Biophys Acta, 1512:191-205.
119. Priebe W, Perez-Soler R. 1993. Design and tumor targeting of anthracyclines able to overcome multidrug resistance: a double-advantage approach. Pharmacol Ther, 60:215-34.
120. Robert NJ, Vogel CL, Henderson IC, et al. 2004. The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Semin Oncol, 31(Suppl 13):106-46.
121. Rose PG 2005. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist, 10:205-14.
122. Sapra P, Allen TM. 2003. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res, 42:439-62.
123. Scherphof GL. 1985. Uptake and intracellular processing of targeted and nontargeted liposomes by rat Kupffer cells in vivo and in vitro. Ann N Y Acad Sci, 446:368-84.
124. Seiden MV, Muggia F, Astrow A, et al. 2004. A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecol Oncol, 93:229-32.
125. Semple SC, Leone R, Wang J, et al. 2005. Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. J Pharm Sci, 94:1024-38.
126. Senior J. 1982. Is half-life of circulating liposomes determined by changes in their permeability? FEBS Lett, 145:109-14.
127. Senior JH. 1987. Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst, 3:123-93.
128. Song LY, Ahkong QF, Rong Q, et al. 2002. Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes. Biochim Biophys Acta, 1558:1-13.
129. Stathopoulos GP, Boulikas T, Vougiouka M, et al. 2005. Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study. Oncol Rep, 13:589-95.
130. Stephenson SM, Low PS, Lee RJ. 2004. Folate receptor-mediated targeting of liposomal drugs to cancer cells. Methods Enzymol, 387:33-50.
131. Stephenson SM, Yang W, Stevens PJ, et al. 2003. Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy. Anticancer Res, 23:3341-45.
132. Strijkers GJ, Mulder WJM, van Heeswijk RB, et al. 2005. Relaxivity of liposomal paramagnetic MRI contrast agents. MAGMA, 18:186-92.
133. Sugano M, Egilmez NK, Yokota SJ, et al. 2000. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res, 60:6942-9.
134. Taira MC, Chiaramoni NS, Pecuch KM, et al. 2004. Stability of liposomal formulations in physiological conditions for oral drug delivery. Drug Deliv, 11:123-8.
135. Takeuchi H, Kojima H, Yamamoto H, et al. 2001. Evaluation of circulation profiles of liposomes coated with hydrophilic polymers having different molecular weights in rats. J Control Release, 75:83-91.
136. Tardi P, Choice E, Masin D, et al. 2000. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res, 60:3389-93.
137. Torchilin VP. 2000. Polymeric contrast agents for medical imaging. Curr Pharm Biotechnol, 1:183-215.
138. Torchilin VP, Levchenko TS, Whiteman KR, et al. 2001. Amphiphilic poly-N-vinylpyrrolidones: synthesis, properties and liposome surface modification. Biomaterials, 22:3035-44.
139. Torchilin VP, Omelyanenko VG, Papisov MI, et al. 1994a. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposomes longevity. Biochim Biophys Acta, 1195:11-20.
140. Torchilin VP, Papisov MI. 1994. Why do polyethylene glycol-coated liposomes circulate so long? J Liposome Res, 4:725-39.
141. Torchilin V, Shtilman M, Trubetskoy V, et al. 1994c. Amphiphilic vinyl polymers selectively prolong liposome circulation time in vivo. Biochim Biophys Acta, 1195:181-4.
142. Torchilin V, Trubetskoy V, Whiteman K, et al. 1995. New synthetic amphiphilic polymers for steric protection of liposomes in vivo. J Pharm Sci, 84:1049-53.
143. Tseng YL, Hong RL, Tao MH, et al. 1999. Sterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma model. Int J Cancer, 80:723-30.
144. Ugwu S, Zhang A, Parmar M, et al. 2005. Preparation, characterization, and stability of liposome-based formulations of mitoxantrone. Drug Dev Ind Pharm, 31:223-9.
145. Veerareddy PR, Vobalaboina V. 2004. Lipid-based formulations of amphotericin B. Drugs Today, 40:133-45.
146. Verschraegen CF, Kumagai S, Davidson R, et al. 2003, Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato (trans-R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles. J Cancer Res Clin Oncol, 129:549-55.
147. Vert M, Domurado D. 2000. Poly(ethylene glycol): protein-repulsive or albumin-compatible? J Biomater Sci Polym Ed, 11:1307-17.
148. Volanakis JE, Narkates AJ. 1981. Interaction of C-reactive protein with artificial phosphatidylcholine bilayers and complement. J Immunol, 126:1820-5.
149. Vorobiof DA, Rapoport BL, Chasen MR, et al. 2004. First line therapy with paclitaxel (Taxol) and pegylated liposomal doxorubicin (Caelyx) in patients with metastatic breast cancer: a multicentre phase II study. Breast, 13:219-26.
150. Whiteman KR, Subr V, Ulbrich K, et al. 2001. Poly(HPMA)-coated liposomes demonstrate prolonged circulation in mice. J Liposome Res, 11:153-64.
151. Woodle M, Engbers C, Zalipsky S. 1994. New amphipatic polymer-lipid conjugates forming long-circulating reticuloendothelial system-evading liposomes. Bioconjug Chem, 5:493-6.
152. Yamaoka T, Tabata Y, Ikada Y. 1994. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration in mice. J Pharm Sci, 83:601-6.
153. Yamauchi H, Yano T, Kato T, et al. 1994. Effects of sialic acid derivative on long circulating time and tumor concentration of liposomes. Int J Pharmacol, 113:141-8.
154. Zalipsky S, Qazen M, Walker JA, et al. 1999. New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. Bioconjug Chem, 10:703-7.
155. Zamboni WC, Gervais AC, Egorin MJ, et al. 2004. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol, 53:329-36.
156. Zamboni WC, Ramalingam S, Friedland DM, et al. 2005. Phase I and pharmacokinetic (PK) study of STEALTH liposomal CKD-602 (S-CKD602) in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts), 23:2069.
157. Zhang JA, Anyarambhatla G, Ma L, et al. 2005. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm, 59:177-87.
158. Zhang JA, Xuan T, Parmar M, et al. 2004a. Development and characterization of a novel liposome-based formulation of SN-38. Int JPharm, 270:93-107.